TENX Shareholder Alert: December 28, 2026 Lead Plaintiff Deadline in Tenax Therapeutics, Inc. Securities Class Action - Contact SueWallSt

Executive Accountability: Chief Medical Officer Stuart Rich is named in the Tenax securities action over his alleged assurances that the Phase 3 LEVEL study of TNX-103 was enriched with the patients most likely to respond. NEW YORK, Oct. 29, 2026 /PRNewswire/ -- SueWallSt notifies investors in Tenax Therapeutics, Inc. (NASDAQ: TENX) that Stuart Rich, M.D.

PRNewsWire • 15 hours ago

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm

Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.

Newsfile Corp • 13 hours ago

TENX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 29, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and reminds investors of the December 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp • 5 hours ago

Kaplan Fox Encourages Tenax Therapeutics, Inc. (TENX) Investors with Significant Losses to Contact the Firm Before December 28, 2026

New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Tenax and have suffered losses, you may CLICK HERE to contact us.

Newsfile Corp • 4 hours ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 28, 2026.

GlobeNewsWire • 7 hours ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENX

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain officers. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 26-cv-01624, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

PRNewsWire • 15 hours ago

TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)---- $TENX #TENX--The case alleges that Tenax Therapeutics and its executives made false and/or misleading statements to investors.

Business Wire • 5 hours ago

Berger Montague PC Investigating Claims on Behalf of Investors in Tenax Therapeutics, Inc. (TENX) After Class Action Filing

Philadelphia, Pennsylvania--(Newsfile Corp. - October 29, 2026) - Berger Montague, a leading national plaintiffs' law firm, announces a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) ("Tenax" or the "Company") on behalf of investors who purchased or otherwise acquired Tenax securities during the period from November 13, 2023 through August 7, 2026 (the "Class Period"). The deadline to apply for lead plaintiff is December 28, 2026.

Newsfile Corp • 14 hours ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

New York, New York--(Newsfile Corp. - October 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

Newsfile Corp • 7 hours ago

Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R.

LOS ANGELES--(BUSINESS WIRE)--Tenax Therapeutics, Inc. ("Tenax" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Tenax Therapeutics, Inc. (NASDAQ: TENX), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Tenax Therapeutics, Inc. on August 10, 2026.If you lost.

Business Wire • 9 hours ago